{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:15:29Z","timestamp":1789852529691,"version":"4.0.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ando.2019.04.003","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T12:15:56Z","timestamp":1554984956000},"page":"159-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Emerging molecular markers of metastatic pheochromocytomas and paragangliomas"],"prefix":"10.1016","volume":"80","author":[{"given":"Judith","family":"Goncalves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lussey-Lepoutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Favier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Paule","family":"Gimenez-Roqueplo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Jaime","family":"Castro-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2019.04.003_bib0320","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2019.04.003_bib0325","first-page":"3296","volume":"102","author":"Hamidi","year":"2017","journal-title":"Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years. J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2019.04.003_bib0330","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis","volume":"87","author":"Hamidi","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2019.04.003_bib0335","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ncpendmet0396","article-title":"Pheochromocytoma: recommendations for clinical practice from the First International Symposium October 2005","volume":"3","author":"Pacak","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.ando.2019.04.003_bib0340","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ando.2019.04.003_bib0345","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2019.04.003_bib0350","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/EJE-14-0113","article-title":"Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma","volume":"171","author":"Baudin","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2019.04.003_bib0355","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/a-0715-1888","article-title":"Spinning towards more promising treatment options","volume":"127","author":"Nolting","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.ando.2019.04.003_bib0360","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ando.2019.04.003_bib0365","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2019.04.003_bib0370","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ando.2019.04.003_bib0375","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1158\/0008-5472.CAN-17-2463","article-title":"Germline mutations in the Mitochondrial 2-Oxoglutarate\/Malate carrier SLC25A11 gene confer a predisposition to metastatic paragangliomas","volume":"78","author":"Buffet","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ando.2019.04.003_bib0380","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1056\/NEJMc066006","article-title":"Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma","volume":"354","author":"Bausch","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2019.04.003_bib0385","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2019.04.003_bib0390","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"characteristics and outcomes of metastatic sdhb and sporadic pheochromocytoma\/paraganglioma: an national institutes of health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ando.2019.04.003_bib0395","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2019.04.003_bib0400","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ando.2019.04.003_bib0405","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2019.04.003_bib0410","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020225","article-title":"The Value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas-a meta-analysis and systematic review of the literature","volume":"11","author":"Stenman","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ando.2019.04.003_bib0415","unstructured":"Lloyd RV OR, K.G., Rosai J. WHO classification of tumours: pathology and genetics of tumours of endocrine organs. (2017)."},{"key":"10.1016\/j.ando.2019.04.003_bib0420","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0046-8177(98)90070-3","article-title":"Prognostic markers in pheochromocytoma","volume":"29","author":"Clarke","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ando.2019.04.003_bib0425","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.MP.0000056982.07160.E3","article-title":"KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma","volume":"16","author":"Elder","year":"2003","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ando.2019.04.003_bib0430","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.prp.2010.01.007","article-title":"Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma","volume":"206","author":"Tavangar","year":"2010","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ando.2019.04.003_bib0435","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1365-2559.1997.2240838.x","article-title":"Expression and prognostic value of c-erbB-2 oncogene product in human phaeochromocytomas","volume":"31","author":"Castilla-Guerra","year":"1997","journal-title":"Histopathology"},{"key":"10.1016\/j.ando.2019.04.003_bib0440","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0002-9440(10)64400-8","article-title":"Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors","volume":"161","author":"Favier","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ando.2019.04.003_bib0445","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1034\/j.1600-0463.2003.1110402.x","article-title":"VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome","volume":"111","author":"Salmenkivi","year":"2003","journal-title":"APMIS"},{"key":"10.1016\/j.ando.2019.04.003_bib0450","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1210\/jc.2002-021299","article-title":"Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma","volume":"88","author":"Boltze","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2019.04.003_bib0455","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ijc.20670","article-title":"Downregulation of metastasis suppressor genes in malignant pheochromocytoma","volume":"114","author":"Ohta","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ando.2019.04.003_bib0460","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1309\/AJCPI8AJLUZ3CZLN","article-title":"Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma","volume":"135","author":"Saffar","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ando.2019.04.003_bib0465","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1245\/s10434-009-0480-y","article-title":"Expression of the transcription factor snail and its target gene twist are associated with malignancy in pheochromocytomas","volume":"16","author":"Waldmann","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ando.2019.04.003_bib0470","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1677\/ERC-09-0049","article-title":"High frequency of SNAIL-expressing cells confirms and predicts metastatic potential of phaeochromocytoma","volume":"16","author":"Hayry","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2019.04.003_bib0475","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/PAS.0b013e3182793dc2","article-title":"Cytoplasmic staining of OCT4 is a highly sensitive marker of adrenal medullary-derived tissue","volume":"37","author":"Alexander","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ando.2019.04.003_bib0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2012.04.032","article-title":"Immunohistochemical evidence of dysregulation of the mammalian target of rapamycin pathway in primary and metastatic pheochromocytomas","volume":"80","author":"Chaux","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.ando.2019.04.003_bib0485","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1530\/EJE-16-0727","article-title":"The clinical utility of circulating neuroendocrine gene transcript analysis in well-differentiated paragangliomas and pheochromocytomas","volume":"176","author":"Peczkowska","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2019.04.003_bib0490","first-page":"484","article-title":"S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas","volume":"115","author":"Unger","year":"1991","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ando.2019.04.003_bib0495","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1677\/ERC-07-0285","article-title":"Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas","volume":"15","author":"Kiss","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2019.04.003_bib0500","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/ERC-12-0267","article-title":"Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation","volume":"20","author":"Kiss","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2019.04.003_bib0505","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1158\/1078-0432.CCR-07-1867","article-title":"Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior","volume":"14","author":"Geli","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2019.04.003_bib0510","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1096-9896(199905)188:1<51::AID-PATH310>3.0.CO;2-R","article-title":"Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas","volume":"188","author":"de Krijger","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.ando.2019.04.003_bib0515","doi-asserted-by":"crossref","first-page":"e0121361","DOI":"10.1371\/journal.pone.0121361","article-title":"Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas","volume":"10","author":"Oudijk","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ando.2019.04.003_bib0520","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1530\/EJE-14-1164","article-title":"Immunohistochemical expression of stem cell markers in pheochromocytomas\/paragangliomas is associated with SDHx mutations","volume":"173","author":"Oudijk","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2019.04.003_bib0525","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5114\/pjp.2013.36004","article-title":"Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas\u00a0\u2013\u00a0a comparative study","volume":"64","author":"Bia\u0142as","year":"2013","journal-title":"Pol J Pathol"},{"key":"10.1016\/j.ando.2019.04.003_bib0530","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/onc.2015.172","article-title":"Rethinking pheochromocytomas and paragangliomas from a genomic perspective","volume":"35","author":"Castro-Vega","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ando.2019.04.003_bib0535","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ando.2019.04.003_bib0540","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1677\/ERC-09-0310","article-title":"Recurrent genomic alterations in benign and malignant pheochromocytomas and paragangliomas revealed by whole-genome array comparative genomic hybridization analysis","volume":"17","author":"Sandgren","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2019.04.003_bib0545","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/modpathol.3801013","article-title":"Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas","volume":"21","author":"Petri","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ando.2019.04.003_bib0550","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1196\/annals.1353.058","article-title":"Gene expression profiling of benign and malignant pheochromocytoma","volume":"1073","author":"Brouwers","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ando.2019.04.003_bib0555","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12022-017-9479-2","article-title":"Malignancy in pheochromocytoma or paraganglioma: integrative analysis of 176 cases in TCGA","volume":"28","author":"Suh","year":"2017","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ando.2019.04.003_bib0560","doi-asserted-by":"crossref","first-page":"e1358332","DOI":"10.1080\/2162402X.2017.1358332","article-title":"Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: relationship with the hypoxic response, immune evasion and malignant behavior","volume":"6","author":"Pinato","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ando.2019.04.003_bib0565","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ando.2019.04.003_bib0570","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1530\/ERC-14-0016","article-title":"The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors","volume":"21","author":"Liu","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2019.04.003_bib0575","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1530\/ERC-13-0429","article-title":"Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia","volume":"21","author":"Papathomas","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2019.04.003_bib0580","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.2174\/1381612820666140630101047","article-title":"Telomere maintenance mechanisms in cancer: clinical implications","volume":"20","author":"Reddel","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ando.2019.04.003_bib0585","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","article-title":"Telomerase activation and atrx mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma","volume":"25","author":"Job","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2019.04.003_bib0590","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/cen.13513","article-title":"Telomerase reverse transcriptase promoter hypermethylation is associated with metastatic disease in abdominal paraganglioma","volume":"88","author":"Svahn","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2019.04.003_bib0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-17-0306","article-title":"TERT structural rearrangements in metastatic pheochromocytomas","volume":"25","author":"Dwight","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2019.04.003_bib0600","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aat6768","article-title":"A mechanistic classification of clinical phenotypes in neuroblastoma","volume":"362","author":"Ackermann","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ando.2019.04.003_bib0605","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00401-017-1690-1","article-title":"Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT","volume":"133","author":"Pekmezci","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ando.2019.04.003_bib0610","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ebiom.2016.03.023","article-title":"Pan-Cancer Analyses Reveal Long Intergenic Non-Coding RNAs Relevant to Tumor Diagnosis, Subtyping and Prognosis","volume":"7","author":"Ching","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ando.2019.04.003_bib0615","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1158\/1078-0432.CCR-14-2804","article-title":"DNA Methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers","volume":"21","author":"de Cubas","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2019.04.003_bib0620","doi-asserted-by":"crossref","first-page":"44943","DOI":"10.1038\/srep44943","article-title":"Global DNA methylation analysis identifies two discrete clusters of pheochromocytoma with distinct genomic and genetic alterations","volume":"7","author":"Backman","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ando.2019.04.003_bib0625","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2019.04.003_bib0630","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-14-2854","article-title":"Spatiotemporal Heterogeneity characterizes the genetic landscape of pheochromocytoma and defines early events in tumorigenesis","volume":"21","author":"Crona","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426619300538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426619300538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:52:22Z","timestamp":1757717542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426619300538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0003426619300538"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2019.04.003","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging molecular markers of metastatic pheochromocytomas and paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2019.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}